Clinical trials: Venous
Central Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
- Trial name
- RAVEN (NCT03810313)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 120 sites in United States, Australia and 18 more
- Volunteers
- 493 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism
A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA
This is a Phase 2, multicenter, randomized, open-label, parallel group, blinded endpoint evaluation, active-controlled, dose-finding study.This study is designed to compare the efficacy and safety of 3 dose levels of SRSD107 and…
- Trial name
- NCT07140523
- Testing
- SRSD107, enoxaparin
- Where
- Czechia
- Volunteers
- 450 people
- Sponsor
- Sirius Therapeutics Co., Ltd.
Surgery, Central Line Associated Blood Stream Infections (CLABSI)
BIP CVC Clinical Safety and Performance Study
The primary objective of this trial was to determine Bactiguard coated BIP CVC's safety and performance and compare it to corresponding standard uncoated CVC.
- Trial name
- NCT02811380
- Testing
- BIP CVC, Uncoated Standard CVC
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Bactiguard AB
Venous Thromboembolism
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
- Trial name
- DaPaR (NCT05536791)
- Testing
- Dabigatran Etexilate (DE)
- Where
- 6 sites in Germany, Netherlands and 2 more
- Sponsor
- Boehringer Ingelheim
Wounds and Injuries, Burns
Clinical Registry Collecting Real World Evidence on Wound Care Treatments
The proposed registry Sponsor (Siddhey LLC) will collect data on various wound treatments in real life settings. Data collection will facilitate the analysis of the safety and efficacy of wound treatments.
- Conditions
- Wounds and Injuries, Burns, Mohs Surgery, Diabetic Foot Ulcer Mixed
- Trial name
- SIDDX (NCT06328010)
- Testing
- Various types of wound care treatments
- Where
- 12 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Siddhey LLC
Venous Leg Ulcer
A Study in Patients With Venous Leg Ulcers and Measuring the Effects of Using Geko™ Device
This is a single centre open label study measuring lower limb physiology in patients with venous leg ulcers at the University Hospital of South Manchester.
- Trial name
- NCT02884323
- Testing
- geko™ device
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Firstkind Ltd
Choroidal Neovascularization, Age-related Macular Degeneration
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV)…
- Trial name
- NCT00379795
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 853 people
- Sponsor
- Genentech, Inc.
Venous Insufficiency
Antistax® in Patients With Chronic Venous Insufficiency
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
- Trial name
- NCT02191280
- Testing
- Antistax®, low dose, Antistax®, high dose
- Volunteers
- 260 people
- Sponsor
- Boehringer Ingelheim
Venous Leg Ulcer
Effect of rhGM-CSF on the Healing of Venous Leg Ulcers
The objective of this study is to examine whether local administration of the growth factor rhGM-CSF incorporated into a hydrogel, can accelerate wound healing when applied to venous leg ulcers, and whether this is safe.
- Trial name
- NCT04823962
- Testing
- rhGM-CSF + hydrogel, Standard care
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Reponex Pharmaceuticals A/S
Chronic Venous Insufficiency, CVI
Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With Flebogrif in Patients With Great Saphenous Vein Insufficiency
The objective of the study is to collect clinical data of patients in whom Flebogrif® will have been used for mechanochemical ablation of incompetent veins in the follow-up period, as related to the safety, clinical…
- Trial name
- POLFLEB (NCT04558957)
- Testing
- FLEBOGRIF
- Where
- 4 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Balton Sp.zo.o.
Coronary Artery Disease
Photochemical Tissue Passivation Treatment of Saphenous Vein Grafts in CABG
Early feasibility study of the DurVena Photochemical Tissue Passivation (PTP) device for treatment of saphenous vein grafts in participants undergoing elective coronary artery bypass graft (CABG) surgery.
- Trial name
- NCT06150872
- Testing
- DurVena Photochemical Tissue Passivation
- Where
- Uzbekistan
- Volunteers
- 4 people
- Sponsor
- DurVena, Inc.
Venous Thrombosis
Switching Study From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when switching the treatment from warfarin to rivaroxaban.
- Trial name
- NCT01507051
- Testing
- Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Vitamin K (Konakion)
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Ataxia
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).
- Trial name
- NCT01428531
- Testing
- Fondaparinux Sodium
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Arrhythmias, Cardiac, Paroxysmal Atrial Fibrillation
InsightPFA Trial of the LotosPFA Catheter
This trial aims to determine whether the InsightPFA for PVI is as effective and safe as standard RFA in the treatment of symptomatic paroxysmal AF.
- Trial name
- InsightPFA (NCT06014996)
- Testing
- Pulsed Field Ablation (PFA) Therapy, Radiofrequency Ablation（RAF）Therapy
- Where
- 10 sites in China
- Volunteers
- 292 people
- Sponsor
- Insight Medtech Co., Ltd.
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
The primary objective was to compare the efficacy of Semuloparin sodium (AVE5026) with Enoxaparin for the prevention of Venous Thromboembolic Events [VTE] in patients undergoing elective knee replacement surgery.
- Trial name
- SAVE-KNEE (NCT00718224)
- Testing
- Semuloparin sodium, Enoxaparin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 1,150 people
- Sponsor
- Sanofi
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Peripheral Arterial Occlusive Disease
GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft
The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
- Trial name
- PRODIGY (NCT00617279)
- Testing
- GORE PROPATEN Vascular Graft, Disadvantaged Autologous Vein Graft
- Where
- 17 sites in United States
- Volunteers
- 31 people
- Sponsor
- W.L.Gore & Associates
Varicose Veins, Veins Diseases
Treatment of Insufficient Superficial and Perforatring Veins of the Lower Limb Using HIFU
This is a one-arm, open label, prospective, single center study to evaluate clinical standardization with Theraclion's Sonovein 2 HIFU device.
- Conditions
- Varicose Veins, Veins Diseases, Varicose Ulcer
- Trial name
- NCT04280679
- Testing
- Sonovein 2
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Theraclion
End Stage Kidney Disease, Chronic Kidney Diseases
The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
This is a global, multi-center, prospective, post-market, confirmatory, interventional, non-randomized, single-arm clinical investigation evaluating arteriovenous fistula (AVF) creation by means of the WavelinQ™ EndoAVF System in…
- Conditions
- End Stage Kidney Disease, Chronic Kidney Diseases, Kidney Failure, Kidney Insufficiency
- Trial name
- WAVE-Global (NCT04626427)
- Testing
- WavelinQ™ EndoAVF System
- Where
- 3 sites in Belgium, Greece and 1 more
- Volunteers
- 21 people
- Sponsor
- C. R. Bard
Pulmonary Embolism, Venous Thromboembolic Disease
Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.
- Trial name
- EVEREST (NCT00556426)
- Testing
- Bard Recovery G2 Filter System
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.